logo

Curis Inc (CRIS)



Trade CRIS now with
  Date
  Headline
12/6/2019 7:32:42 AM Curis Announces Updated Preliminary Data From Phase 1 Dose Escalation Study Of CA-4948
12/6/2019 7:02:22 AM Curis Announces Positive Safety, Tolerability And Pharmacokinetic Data In Phase 1 Study Of Fimepinostat With Venetoclax
11/5/2019 7:02:39 AM Curis Q3 Net Loss Narrows To $6.4 Mln Or $0.19/shr From $7.2 Mln Or $0.22/shr Prior Year
9/12/2019 8:04:51 AM Curis Says Promotes Bill Steinkrauss To CFO
8/6/2019 4:02:56 PM Curis Q2 Loss Per Share $0.22 Vs Loss $0.26 Last Year
7/5/2019 4:06:42 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/12/2019 7:03:13 AM Curis Highlights Publication In Nature Cell Biology Identifying Cancer-Causing Form Of IRAK4 In Patients With AML, MDS
5/14/2019 4:08:10 PM Curis Q1 Loss/share $0.30 Vs. Loss $0.33 Year Ago
5/6/2019 8:03:18 AM Curis Completes Mesothelioma Enrollment In CA-170 Study
4/10/2019 8:02:10 AM Curis Regains Compliance With Nasdaq Continued Listing Requirements
4/5/2019 4:52:50 PM Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/26/2019 4:05:45 PM Curis Q4 Loss/share $0.18 Vs. Loss $0.24 Year Ago
  
 
>